Read by QxMD icon Read

Macular oedema

Alice Laroni, Davide Brogi, Vincenzo Brescia Morra, Leonello Guidi, Carlo Pozzilli, Giancarlo Comi, Alessandra Lugaresi, Renato Turrini, Debora Raimondi, Antonio Uccelli, Giovanni Luigi Mancardi
: The safety profile of fingolimod is well established in clinical trials and post-marketing studies. This study aimed to evaluate the safety and tolerability of fingolimod in a cohort of Italian patients with relapsing-remitting multiple sclerosis (RRMS). This is a non-comparative, open-label, multicentre, interventional study conducted in patients with RRMS with no suitable alternative treatment option. Safety and tolerability of fingolimod 0.5 mg were assessed by recording adverse events (AEs) and serious AEs (SAEs)...
October 18, 2016: Neurological Sciences
Mark D Willis, Trevor P Pickersgill, Neil P Robertson, Richard W J Lee, Andrew D Dick, Ester Carreño
PURPOSE: The purpose of the study was to report a case of multiple sclerosis (MS)-associated uveitis refractory to conventional immunosuppressants, with subsequent remission following treatment with alemtuzumab. METHODS: Case report Patient was treated with intravenous alemtuzumab, a lymphocyte depleting anti-CD52 monoclonal antibody that has recently been approved for use in relapsing MS. RESULTS: A 17-year-old female presented with bilateral optic neuritis and subsequently bilateral intermediate uveitis and secondary macular oedema...
October 11, 2016: International Ophthalmology
Stacey A Strong, Avinash Gurbaxani, Michel Michaelides
BACKGROUND: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that responded on two separate occasions to intravitreal injections of aflibercept, despite previously demonstrating only minimal response to intravitreal ranibizumab. This unique case would support a trial of intravitreal aflibercept for the treatment of RP-associated cystoid macular oedema. CASE PRESENTATION: A 38-year-old man from Dubai, United Arab Emirates, presented to the UK with a 3-year history of bilateral RP-associated cystoid macular oedema...
May 2016: Case Reports in Ophthalmology
Francesco Boscia, Ermete Giancipoli, Giuseppe D'Amico-Ricci, Antonio Pinna
PURPOSE OF REVIEW: The aim of this study was to describe all the treatment modalities used to prevent and manage macular oedema in diabetic patients undergoing cataract surgery. RECENT FINDINGS: Topical NSAIDs have been proposed to be an effective strategy to prevent postsurgical macular oedema (PME) in diabetic patients. The prophylactic use of intravitreal antivascular endothelial growth factors (anti-VEGF) drugs and steroids in these patients, even if effective, brings some concerns with regard to possible side effects...
September 21, 2016: Current Opinion in Ophthalmology
Chuandi Zhou, Qiurong Lin, Fenge Chen
AIMS: To evaluate the prevalence of metamorphopsia after successful rhegmatogenous retinal detachment (RRD) surgery and determine the independent predictors of metamorphopsia. METHODS: A cross-sectional, comparative study. The study included 380 eyes of 357 patients who underwent a successful RRD surgery between 2009 and 2015. The presence of metamorphopsia was tested with an Amsler grid and the foveal microstructure was scanned with high-resolution spectral-domain optical coherence tomography (OCT) at a follow-up visit...
September 15, 2016: British Journal of Ophthalmology
Pierluigi Iacono, Maurizio Battaglia Parodi, Matteo Scaramuzzi, Francesco Bandello
BACKGROUND: To evaluate the effects of dexamethasone implant in eyes affected by recalcitrant diabetic macular oedema (DME) associated with proliferative diabetic retinopathy (PDR). METHODS: Thirteen consecutive patients with centre-involving DME associated with PDR, central macular thickness (CMT) ≥300 µm, previous therapy with panretinal photocoagulation, focal/grid laser treatment and anti-vascular endothelial growth factor injection were prospectively enrolled...
September 13, 2016: British Journal of Ophthalmology
Joseph Daniel Boss, Philip Lieu, Asheesh Tewari
We describe the management of subretinal fluid and macular oedema due to colorectal cancer metastasis to the choroid using intravitreal bevacizumab. A patient with grade VI KRAS mutation rectal cancer with metastasis to the lung and cerebellum presented with left eye choroidal metastasis 1 week after being started on the experimental medication KTN3379. After intravitreal bevacizumab administration, the patient had improvement in macular subretinal fluid, but eventually progressed to severe cystoid macular oedema despite monthly intravitreal bevacizumab treatment...
2016: BMJ Case Reports
Shin-Yu Chang, Shawn H Tsai, Lee-Jen Chen, Wei-Chun Chan
No abstract text is available yet for this article.
August 22, 2016: Acta Ophthalmologica
António Campos, Elisa J Campos, João Martins, António Francisco Ambrósio, Rufino Silva
Diabetic macular oedema (DMO) is the leading cause of vision loss in the working-age population. Blood-retinal barrier (BRB) dysfunction in diabetic retinopathy (DR), mainly at the level of the retinal vessels, has long been related with leakage and fluid accumulation, leading to macular oedema. However, the nourishment of the macula is provided by the choroid and a diabetic choroidopathy has been described. Therefore, there has been a growing interest in studying the role of the choroid in the pathophysiology of DR and DMO, mainly by optical coherence tomography (OCT)...
August 22, 2016: Acta Ophthalmologica
Jaume Català-Mora, Daniel Cuadras, Jesús Díaz-Cascajosa, Marta Castany-Aregall, Joan Prat-Bartomeu, José García-Arumí
PURPOSE: To report the feasibility and long-term safety of lensectomy and iris-claw intraocular lens (IOL) implantation to treat children with severe ectopia lentis in a paediatric tertiary hospital. METHODS: Prospective cohort study of 21 eyes from 12 patients with severe ectopia lentis and visual acuity <20/63. All eyes underwent 23-gauge pars plana vitrectomy, lensectomy, iridectomy and Artisan IOL implantation in the anterior chamber with iris-claw enclavation via pars plana...
August 18, 2016: Acta Ophthalmologica
Kanmin Xue, Elizabeth Yang, N Victor Chong
AIMS: To characterise differential pathogeneses of diabetic macular oedema (DMO) using ultra-widefield fluorescein angiography (UWFA) and evaluate responses to anti-vascular endothelial growth factor (anti-VEGF) therapy. METHODS: Ninety-nine eyes (73 consecutive patients) with anti-VEGF naïve DMO underwent UWFA and optical coherence tomography, of which 60 with central retinal thickness (CRT) >400 μm received monthly intravitreal ranibizumab injections. Best-corrected visual acuity (BCVA) and CRT were measured at baseline and after three injections...
August 16, 2016: British Journal of Ophthalmology
Taiji Hasegawa, Mariko Yamashita, Ichiro Maruko, Hideki Koizumi, Akiko Kogure, Nahoko Ogata, Tomohiro Iida
AIM: To determine whether the low reflective spaces in the retinal nerve fibre layer (RNFL) in the optical coherence tomographic (OCT) images are related to the presence of the retinal non-perfused areas in eyes with macular oedema associated with a retinal vein occlusion (RVO). METHODS: We reviewed the medical records of 97 eyes with macular oedema associated with RVO. At the initial visit, eyes with macular oedema were classified into those with and those without low reflective spaces in the RNFL in the OCT images...
August 16, 2016: British Journal of Ophthalmology
Sara Touhami, Christine Fardeau, Antoine Vanier, Olivia Zambrowski, Rafaela Steinborn, Claude Simon, Sophie Tezenas du Montcel, Bahram Bodaghi, Phuc Lehoang
PURPOSE: To determine the prognostic factors of long-term visual outcome in birdshot retinochoroidopathy (BRC). METHODS: Design: Retrospective case series. Study Population: Successive HLA-A29+ BRC patients whose latest visit was between May and August 2013 at a single tertiary center (Pitié-Salpétrière Hospital, Paris). OBSERVATION PROCEDURE: Endpoint visual status (remission or deterioration) was determined for each patient based on clinical and ancillary data from the latest visit including optical coherence tomography (OCT), automated visual field (AVF), and angiograms...
October 2016: American Journal of Ophthalmology
E A Stewart, S Saker, W M Amoaku
Diabetic macular oedema (DMO), a leading cause of preventable visual loss in the working population, is caused by an increase in microvascular endothelial cell permeability, and its prevalence is on the increase in parallel with the rising worldwide prevalence of diabetes. It is known that retinal vascular leakage in DMO is contributed to by VEGF upregulation as well as non-VEGF dependent inflammatory pathways, and the potential use of anti-inflammatory agents such as the glucocorticoids, including dexamethasone are being extensively studied...
October 2016: Experimental Eye Research
R Rewbury, A Want, R Varughese, V Chong
PurposeTo investigate the relationship between subfoveal choroidal thickness, severity of diabetic retinopathy (DR), and the presence of diabetic macular oedema (DMO) using enhanced depth imaging spectral domain optical coherence tomography (EDI-OCT) in patients with type 2 diabetes.MethodsA retrospective study of 145 eyes from untreated, type 2 diabetic patients who attended clinic at the Oxford Eye Hospital between January 2012 and February 2013, and underwent fundus photography and EDI-OCT imaging. Eyes were divided into two groups based on the presence or absence of foveal involving DMO and classified according to retinopathy grade: R1 (mild non-proliferative diabetic retinopathy (NPDR), R2 (moderate-severe NPDR), and R3 (proliferative diabetic retinopathy (PDR)...
August 12, 2016: Eye
Yasemin Ozdamar Erol, Pergin Atilla, Golge Acaroglu, Sevda Muftuoglu, Jale Karakaya
The aim of this study is to investigate the histopathological features of Tenon's capsule in eyes with diabetic macular oedema and to compare them between diabetic eyes and healthy subjects. The study included 26 eyes with diabetic oedema and 17 healthy eyes as healthy controls. Tenon's capsule biopsy specimens were processed with the routine electron microscopic analysis technique. Type I and III collagen fibres were labelled immunohistochemically to determine the amounts of predominating collagen fibres. Leica Q-Win program was used to calculate the amounts of collagen fibres type I and type III and independent-t test was utilized to compare the obtained results between the groups...
August 11, 2016: International Ophthalmology
Nopasak Phasukkijwatana, Anna C S Tan, Xuejing Chen, K Bailey Freund, David Sarraf
BACKGROUND/AIMS: To assess the microvascular response of type 3 neovascularisation secondary to age-related macular degeneration (AMD) after antivascular endothelial growth factor (anti-VEGF) therapy using optical coherence tomography angiography (OCTA). METHODS: Consecutive patients diagnosed with AMD and type 3 neovascularisation based on clinical examination, structural optical coherence tomography and fluorescein angiography when available were retrospectively evaluated...
August 8, 2016: British Journal of Ophthalmology
Karen M Wai, Mehnaz Khan, Sunil Srivastava, Aleksandra Rachitskaya, Fabiana Q Silva, Ryan Deasy, Andrew P Schachat, Amy Babiuch, Justis P Ehlers, Peter K Kaiser, Alex Yuan, Rishi P Singh
AIM: To determine the impact of initial visual acuity (VA) on anti-vascular endothelial growth factor (VEGF) treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice. METHODS: A retrospective study was conducted at a single academic institution to identify 177 treatment naïve patients with macular oedema secondary to branch retinal vein occlusion (BRVO), hemiretinal vein occlusion (HRVO) and central retinal vein occlusion (CRVO) treated with intravitreal anti-VEGFs...
August 8, 2016: British Journal of Ophthalmology
Gavin S Tan, Ning Cheung, Rafael Simó, Gemmy C M Cheung, Tien Yin Wong
Diabetic macular oedema, characterised by exudative fluid accumulation in the macula, is the most common form of sight-threatening retinopathy in people with diabetes. It affects one in 15 people with diabetes resulting in more than 20 million cases worldwide. Few epidemiological studies have been done to specifically investigate risk factors for diabetic macular oedema, although poor glycaemic and blood pressure control are associated with the presence and development of the disorder. The pathophysiological processes begin with chronic hyperglycaemia, and interplay between vascular endothelial growth factor (VEGF) and inflammatory mediators...
August 2, 2016: Lancet Diabetes & Endocrinology
Pedro Romero-Aroca, Sofia de la Riva-Fernandez, Aida Valls-Mateu, Ramon Sagarra-Alamo, Antonio Moreno-Ribas, Nuria Soler, Domenec Puig
BACKGROUND: Prospective, population-based study of an 8-year follow up. To determine the direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of treating DR, focusing on diabetic macular oedema [DMO] after anti-vascular endothelial growth factor [anti-VEGF] treatment. METHODS: A total of 15,396 diabetes mellitus [DM] patients were studied. We determined the cost-effectiveness of our screening programme against an annual programme by applying the Markov simulation model...
2016: BMC Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"